Company Overview and News

 
Short Sellers Look for Direction in Solar, Alt Energy Stocks

4h 247wallst
Short interest moves among solar and alternative energy stocks were mixed during the two-week reporting period that ended on April 13. Of the companies we watch, short interest fell on two of three solar stocks and fell on two of four alternative energy stocks.
Upvote Downvote

 
First Solar (FSLR) to Report Q1 Earnings: A Beat in Store?

2018-04-24 zacks
First Solar, Inc. (FSLR - Free Report) is scheduled to report first-quarter 2018 results after the market closes on Apr 26. Last quarter, the company delivered a positive earnings surprise of 21.88%. Let’s see how things are shaping up prior to this announcement. Factors at Play As a result of strong Series 4 bookings in the fourth quarter of 2017, First Solar decided to restart two lines of Series 4 production in Ohio, which were shut down in late 2017.
Upvote Downvote

 
Energy Recap: A Look At SunPower's Planned Purchase Of Rival SolarWorld Americas

2018-04-20 seekingalpha
Every Friday, Seeking Alpha provides a roundup of insightful opinion and analysis articles in the energy sector.
Upvote Downvote

 
SunPower (SPWR) Signs Deal to Acquire SolarWorld Americas

2018-04-20 zacks
In a bid to evolve as the largest U.S. solar panel manufacturer, SunPower Corp. (SPWR - Free Report) recently signed an agreement to acquire its long-time competitor SolarWorld Americas. Notably, the acquiree is the largest solar panel manufacturer in the United States. The terms of the deal have been kept under the wraps and are subject to necessary U.S. and German regulatory approvals, with the acquiree being the American subsidiary of German module manufacturer SolarWorld.
Upvote Downvote

 
SunPower Dumps Trump Tariffs

2018-04-19 seekingalpha
One of the largest secular trends for the next few decades will be the buildout of alternative energy globally. Solar in particular, will be vitally important as estimates range that from 30-50% of all electricity will come from solar by mid-century or sooner.
Upvote Downvote

 
U.S. Set to Edge China Out in the Solar Race

2018-04-19 zacks
As solar energy keeps getting cheaper by the day, countries across the globe are fast adapting to the clean energy source to fulfil all energy needs. Countries like China have stepped up their game by investing significantly in cutting-edge technologies related to solar energy. As a matter of fact, China has also surpassed the United States when it comes to investing in clean energy. This has led to speculation about the future of solar energy in the United States and whether it would lose to China in the solar race.
Upvote Downvote

 
Capture First Solar, Inc. Stock’s Scorching Profits While You Still Can

2018-04-18 investorplace
I hate to admit it, but First Solar, Inc. (NASDAQ:FSLR) is having a brilliant time in the markets. Year-to-date, FSLR stock isn’t that remarkable, up around 15%. However, over the trailing year, First Solar tore up the markets, returning shareholders a whopping 170% return.
Upvote Downvote

 
SunPower buys US rival SolarWorld to head off Trump tariffs

2018-04-18 channelnewsasia
SunPower Corp on Wednesday said it would buy U.S. solar panel maker SolarWorld Americas, expanding its domestic manufacturing as it seeks to stem the impact of Trump administration tariffs on panel imports.
Upvote Downvote

 
SunPower heads off Trump tariffs with SolarWorld purchase - Channel NewsAsia

2018-04-18 channelnewsasia
REUTERS: SunPower Corp on Wednesday said it would buy U.S. solar panel maker SolarWorld Americas, expanding its domestic manufacturing as it seeks to stem the impact of Trump administration tariffs on panel imports.
Upvote Downvote

 
SunPower heads off Trump tariffs with SolarWorld purchase

2018-04-18 reuters
(Reuters) - SunPower Corp (SPWR.O) on Wednesday said it would buy U.S. panel maker SolarWorld Americas, dramatically expanding its domestic manufacturing as it seeks to stem the impact of Trump administration tariffs on solar imports.
Upvote Downvote

 
TOTAL to Expand Electric & Gas Operation Via Acquisition

2018-04-18 zacks
TOTAL S.A. (TOT - Free Report) announced that it has entered into a definite agreement with the controlling shareholders of Direct Energie to acquire 74.33% of its share capital. Price of each share is fixed at €42 ($51.96) and ex-dividend at €0.35 (43.3 cents) per share, representing an aggregate acquisition price of approximately €1.4 billion ($1.73 billion). The acquisition of majority of Direct Energie’s interest will help TOTAL to expand its electric and gas generation, and distribution operation in France and Belgium.
Upvote Downvote

 
Is JA Solar Holdings' Stagnant, Declining Share Price Going To Get Worse?

2018-04-17 seekingalpha
A high probability that companies such as JA Solar will be exposed to the detrimental effects of ‘trade wars’ and geopolitical uncertainty that are currently ensuing.
Upvote Downvote

 
Zacks Industry Outlook Highlights: Jinko Solar, Azure Power Global, Dominion Midstream, SunPower and NextEra Energy Partners

2018-04-17 zacks
Chicago, IL – April 17, 2018 – Today, Zacks Equity Research discusses the Industry: Alternative Energy, Part 3, including Jinko Solar (JKS - Free Report) , Azure Power Global (AZRE - Free Report) , Dominion Midstream (DM - Free Report) , SunPower Corp (SPWR - Free Report) and NextEra Energy Partners (NEP - Free Report) .
Upvote Downvote

 
Will Solar Import Tariffs Hurt U.S. Alternative Energy?

2018-04-16 zacks
China’s emergence as a global leader of investment in clean energy projects poses serious threat to U.S based operators for the Alternative Energy industry. China has been a frontrunner in terms of solar module manufacturing and it has made substantial wind power investments in 2017 to expand its renewables footprint worldwide.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 867652406